AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Pipeline Review for Caspase 3 - H1 2020 - ResearchAndMarkets.com

February 3, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Feb 3, 2020--

The “Caspase 3 - Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This pipeline outlays comprehensive information on the Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Reasons to buy

Companies Mentioned

Scope

Key Topics Covered:

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/noaxgs

View source version on businesswire.com:https://www.businesswire.com/news/home/20200203005578/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 02/03/2020 10:58 AM/DISC: 02/03/2020 10:58 AM

http://www.businesswire.com/news/home/20200203005578/en